
GSK-1004723 (CHEM131719)
| Record Information | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Version | 1.0 | ||||||||||||
| Creation Date | 2026-04-14 19:05:03 UTC | ||||||||||||
| Update Date | 2026-08-22 12:15:20 UTC | ||||||||||||
| Accession Number | CHEM131719 | ||||||||||||
| Identification | |||||||||||||
| Common Name | GSK-1004723 | ||||||||||||
| Class | Small Molecule | ||||||||||||
| Description | GSK-1004723 is an organic compound with the chemical formula C39H49ClN4O2. GSK-1004723 belongs to the benzodiazines, a subclass of diazanaphthalenes within the organic compounds. With an average molecular weight of 641.30 g/mol, GSK-1004723 is a heavy molecule. This organoheterocyclic compound acts as an antagonist for two protein targets: the Histamine H1 receptor (HRH1) and the Histamine H3 receptor (HRH3). | ||||||||||||
| Contaminant Sources | Not Available | ||||||||||||
| Contaminant Type | Not Available | ||||||||||||
| Chemical Structure | |||||||||||||
| Synonyms | Not Available | ||||||||||||
| Chemical Formula | C39H49ClN4O2 | ||||||||||||
| Average Molecular Mass | 641.300 g/mol | ||||||||||||
| Monoisotopic Mass | 640.354 g/mol | ||||||||||||
| CAS Registry Number | 955359-72-5 | ||||||||||||
| IUPAC Name | 2-{[(2R)-1-(4-{4-[3-(azepan-1-yl)propoxy]phenyl}butyl)pyrrolidin-2-yl]methyl}-4-[(4-chlorophenyl)methyl]-1,2-dihydrophthalazin-1-one | ||||||||||||
| Traditional Name | Not Available | ||||||||||||
| SMILES | ClC1=CC=C(CC2=NN(C[C@H]3CCCN3CCCCC3=CC=C(OCCCN4CCCCCC4)C=C3)C(=O)C3=CC=CC=C23)C=C1 | ||||||||||||
| InChI Identifier | InChI=1S/C39H49ClN4O2/c40-33-19-15-32(16-20-33)29-38-36-13-3-4-14-37(36)39(45)44(41-38)30-34-12-9-27-43(34)26-8-5-11-31-17-21-35(22-18-31)46-28-10-25-42-23-6-1-2-7-24-42/h3-4,13-22,34H,1-2,5-12,23-30H2/t34-/m1/s1 | ||||||||||||
| InChI Key | YANGEESWIGIKOP-UUWRZZSWSA-N | ||||||||||||
| Chemical Taxonomy | |||||||||||||
| Classification | Not classified | ||||||||||||
| Biological Properties | |||||||||||||
| Status | Detected and Not Quantified | ||||||||||||
| Origin | Not Available | ||||||||||||
| Cellular Locations | Not Available | ||||||||||||
| Biofluid Locations | Not Available | ||||||||||||
| Tissue Locations | Not Available | ||||||||||||
| Pathways |
| ||||||||||||
| Applications | Not Available | ||||||||||||
| Biological Roles | Not Available | ||||||||||||
| Chemical Roles | Not Available | ||||||||||||
| Physical Properties | |||||||||||||
| State | Not Available | ||||||||||||
| Appearance | Not Available | ||||||||||||
| Experimental Properties |
| ||||||||||||
| Predicted Properties | Not Available | ||||||||||||
| Spectra | |||||||||||||
| Spectra |
| ||||||||||||
| Toxicity Profile | |||||||||||||
| Route of Exposure | Not Available | ||||||||||||
| Mechanism of Toxicity | Not Available | ||||||||||||
| Metabolism | Not Available | ||||||||||||
| Toxicity Values | Not Available | ||||||||||||
| Lethal Dose | Not Available | ||||||||||||
| Carcinogenicity (IARC Classification) | Not Available | ||||||||||||
| Uses/Sources | Not Available | ||||||||||||
| Minimum Risk Level | Not Available | ||||||||||||
| Health Effects | Not Available | ||||||||||||
| Symptoms | Not Available | ||||||||||||
| Treatment | Not Available | ||||||||||||
| Concentrations | |||||||||||||
| Not Available | |||||||||||||
| External Links | |||||||||||||
| Identifiers | Not Available | ||||||||||||
| References | |||||||||||||
| Synthesis Reference | Not Available | ||||||||||||
| MSDS | Not Available | ||||||||||||
| General References | Not Available | ||||||||||||